Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Jun 28, 2009; 15(24): 2960-2974
Published online Jun 28, 2009. doi: 10.3748/wjg.15.2960
Published online Jun 28, 2009. doi: 10.3748/wjg.15.2960
Table 3 Drugs that may need to be administered at reduced doses in patients with liver cirrhosis[187]
Drugs with high first-pass effect | Drugs metabolized mainly by | ||
CYP 1A2 | CYP3A4 | CYP2C9 | |
Amitriptyline | Acetaminophen | Quinidine | Diclofenac |
Bromocriptine | Caffeine | Amiodarone | Ibuprofen |
Diltiazem | Mexiletine | Lidocaine | Mefenamic acid |
Flumazenil | (R)-Warfarin | Midazolam | Tolbutamide |
Fluorouracil | Imipramine | Diazepam | Phenytoin |
Imipramine | Theophylline | Amitriptyline | Phenobarbital |
Isosorbide dinitrate | Propranolol | Imipramine | (S)-Warfarin |
Labetalol | Tamoxifen | Carbamazepine | Losartan |
Lidocaine | Estradiol | (R)-Warfarin | Piroxicam |
Morphine | Erythromycin | ||
Nifedipine | Clarithromycin | ||
Pentazocine | |||
Propranolol | |||
Verapamil |
- Citation: Minemura M, Tajiri K, Shimizu Y. Systemic abnormalities in liver disease. World J Gastroenterol 2009; 15(24): 2960-2974
- URL: https://www.wjgnet.com/1007-9327/full/v15/i24/2960.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.2960